07:55 AM EDT, 09/30/2024 (MT Newswires) -- Adicet Bio ( ACET ) said Monday it has opened enrollment for its phase 1 trial evaluating ADI-001, an investigational allogeneic gamma delta CAR T cell therapy, in autoimmune diseases.

The company said it is enrolling patients with lupus nephritis and plans to accept patients with systemic lupus erythematosus, systemic sclerosis, and anti-neutrophil cytoplasmic autoantibody-associated vasculitis in Q4.

Preliminary data from the study are expected in H1 2025, Adicet Bio ( ACET ) said.

Shares of the company were up 5.6% in recent Monday premarket activity.

Price: 1.5100, Change: +0.08, Percent Change: +5.59